Central Contact Ft. Worth,
The purpose of this study is to investigate the long-term efficacy and safety of posterior
juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.
- Patients with subfoveal exudative age-related macular degeneration (AMD) who were
previously enrolled in long-term studies with anecortave acetate.
- Other protocol-defined inclusion criteria may apply.
- Other protocol-defined exclusion criteria may apply.